CNO Financial Group, Inc.

CNO Financial Group, Inc. (CNO) Market Cap

CNO Financial Group, Inc. has a market capitalization of $4.11B.

Financials based on reported quarter end 2025-12-31

Price: $43.61

-0.33 (-0.75%)

Market Cap: 4.11B

NYSE · time unavailable

CEO: Gary Chandru Bhojwani

Sector: Financial Services

Industry: Insurance - Life

IPO Date: 2003-09-10

Website: https://www.cnoinc.com

CNO Financial Group, Inc. (CNO) - Company Information

Market Cap: 4.11B · Sector: Financial Services

CNO Financial Group, Inc., through its subsidiaries, develops, markets, and administers health insurance, annuity, individual life insurance, and other insurance products for senior and middle-income markets in the United States. It offers Medicare supplement, supplemental health, and long-term care insurance policies; life insurance; and annuities, as well as Medicare advantage plans to individuals through phone, online, mail, and face-to-face. The company also focuses on worksite and group sales for businesses, associations, and other membership groups by interacting with customers at their place of employment. In addition, it provides fixed index annuities; fixed interest annuities, including fixed rate single and flexible premium deferred annuities; single premium immediate annuities; supplemental health products, such as specified disease, accident, and hospital indemnity products; and long-term care plans primarily to retirees and older self-employed individuals in the middle-income market. Further, the company offers universal life and other interest-sensitive life products; and traditional life policies that include whole life, graded benefit life, term life, and single premium whole life products, as well as graded benefit life insurance products. CNO Financial Group, Inc. markets its products under the Bankers Life, Washington National, and Colonial Penn brand names. The company sells its products through agents, independent producers, and direct marketing. CNO Financial Group, Inc. was founded in 1979 and is headquartered in Carmel, Indiana.

Analyst Sentiment

62%
Buy

Based on 17 ratings

Analyst 1Y Forecast: $46.67

Average target (based on 3 sources)

Consensus Price Target

Low

$43

Median

$47

High

$50

Average

$47

Potential Upside: 7.0%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CNO FINANCIAL GROUP INC (CNO) — Investment Overview

🧩 Business Model Overview

CNO Financial Group Inc is a U.S.-focused insurance holding company specializing in life insurance, supplemental health products, and annuities. Through its family of insurance brands—including Bankers Life, Washington National, and Colonial Penn—CNO serves primarily middle-income consumers and retirees, which represents a large and often underserved market segment. The company leverages both captive (career) agents and independent distribution channels to reach customers in all 50 states, offering vital protection and retirement solutions designed to address longevity, healthcare costs, and accessibility gaps. CNO operates as a multi-brand organization with distinct sales forces targeting specific demographics. Its distribution is supported by a combination of face-to-face, telephonic, and digital engagement, enabling the company to adapt to evolving consumer preferences. CNO’s business is rooted in underwriting, investment of collected premiums, risk management, and customer-centric sales practices. Its vertically integrated model allows for full control over product design, pricing, marketing, and customer service, resulting in strong brand recognition and deep customer relationships.

💰 Revenue Streams & Monetisation Model

CNO generates revenue primarily through: - **Premiums from insurance products:** The company collects regular premiums from life insurance, health insurance, supplemental policies (such as long-term care, cancer, accident, and critical illness), and annuity contracts. - **Net investment income:** A significant driver of earnings is the income generated from investing policyholder funds, primarily in fixed income securities, mortgage-backed securities, and other conservative assets aligned with long-term liabilities. - **Fee income:** Ancillary revenues come from service fees, administrative charges, and product riders (such as living benefits or return-of-premium features). - **Product mix and persistency:** Revenue stability is enhanced by the mix of recurring premiums and persistency rates, as long-term policy retention contributes to predictable cash flows and profitability. CNO’s monetisation strategy relies on underwriting discipline, active product management, and frequent innovation, enabling cross-selling and upselling opportunities across its customer base.

🧠 Competitive Advantages & Market Positioning

CNO has established a defensible position in the insurance marketplace by: - **Targeting middle-income Americans:** This segment is frequently overlooked by larger insurers that focus on either mass-market group products or high-net-worth individuals. CNO’s specialized knowledge of this demographic enables tailored product design and underwriting. - **Multi-channel distribution:** The company’s hybrid of captive agents, independent brokers, and direct-to-consumer capabilities increases its reach and supports a highly personalized sales approach. - **Recognized brand portfolio:** Established legacy brands—such as Bankers Life and Colonial Penn—carry extensive trust and brand equity within their target populations, bolstered by years of advertising and community presence. - **Relationship-driven sales:** The emphasis on direct sales interactions and ongoing client servicing enhances persistency and customer loyalty, reducing acquisition costs and attrition rates. - **Technology and operational efficiency:** Investments in digital tools, analytics, customer portals, and modernized processes have improved underwriting, claims management, and cross-selling efficacy. These advantages provide CNO with relatively stable margins and the flexibility to respond to shifts in consumer behavior or competitive dynamics.

🚀 Multi-Year Growth Drivers

CNO’s potential for multi-year growth centers on several structural and execution-driven opportunities: - **Aging U.S. population:** As the baby boomer generation enters retirement, demand for supplemental health, long-term care, and guaranteed income vehicles is expected to rise, playing to CNO’s product strengths. - **Underinsurance gap:** Middle-income households remain underinsured, especially regarding supplemental health and retirement income products, leaving substantial room for penetration and cross-selling. - **Digital transformation:** Continued digitalization of marketing, distribution, and servicing enables CNO to reach new customer segments more efficiently, reduce distribution costs, and improve customer experience. - **Product innovation:** Ongoing development of flexible, consumer-friendly insurance solutions—such as hybrid life/long-term care and simplified-issue policies—drives new sales and retention. - **Expanding voluntary benefit offerings:** Growth in worksite benefits through businesses and organizations offers incremental sales channels and diversification of product mix. - **Margin expansion through efficiency:** Operational improvements and technology-driven efficiencies can enhance profitability through lower unit costs and improved risk analytics. The company’s ability to leverage these growth vectors while maintaining disciplined underwriting is critical to sustained earnings and value creation.

⚠ Risk Factors to Monitor

Investors should be mindful of key risk factors, including: - **Interest rate sensitivity:** As with most life insurers, CNO’s earnings are exposed to fluctuations in interest rates, which affect investment returns and the valuation of long-duration liabilities. - **Underwriting risk:** Unexpected increases in claims experience (for example, due to pandemics, adverse mortality, or morbidity trends) can pressure margins and reserve adequacy. - **Regulatory and legislative changes:** Shifts in state or federal insurance regulation, such as reserve requirements, product approvals, or healthcare policy reforms, can affect profitability and product offerings. - **Competition:** The middle-market insurance segment is subject to competition from both large national insurers and specialized regional players, leading to pricing and margin pressures. - **Execution risk:** Failure to deliver on digital initiatives, new product launches, or agent force dynamics could undermine growth targets. - **Reputational and operational risks:** Customer-facing missteps, cybersecurity breaches, or compliance failures could damage brand trust and financial outcomes. Close monitoring of these risks and mitigation strategies is essential for investment prudence.

📊 Valuation & Market View

CNO is typically valued relative to its peers on multiples such as price-to-earnings (P/E), price-to-book (P/B), and price-to-embedded value. The company often trades at a discount to larger life and health insurers, reflecting its focus on the middle-income market, somewhat lower diversification, and more moderate growth rates. However, its consistent profitability, capital-generation profile, and prudent balance sheet management often support a reliable dividend and share repurchase activity. Consensus view frequently recognizes CNO’s stable business model and attractive return on equity, though it notes the company’s sensitivity to macroeconomic factors—particularly interest rates and the credit environment. Investors may consider the valuation compelling if they believe CNO can sustain its franchise, improve profitability through digital transformation, and benefit from demographic tailwinds in the years ahead.

🔍 Investment Takeaway

CNO Financial Group Inc presents a focused play on the enduring need for insurance and retirement solutions among America’s middle-income households. The company’s multi-brand platform, relationship-driven distribution, and ongoing investment in technology position it well to capture growth from underpenetrated segments and aging demographics. While not without risk—including interest rate sensitivity and execution challenges—CNO’s stable recurring revenues, conservative reserve practices, and capital strength offer a measure of downside protection. For long-term investors seeking exposure to the insurance sector with an emphasis on stable dividends, prudent management, and the potential for operational leverage, CNO merits consideration as a core holding within the mid-cap financial landscape.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"CNO (latest: 2025-12-31) reported Revenue of $1.143B and Net Income of $92.9M (EPS $0.98). QoQ Revenue declined ( $1.1887B → $1.1431B, -3.8% ), while Net Income surged ( $23.1M → $92.9M, +302%). YoY, Revenue grew ( $1.0972B → $1.1431B, +4.2% ), but Net Income fell ( $166.1M → $92.9M, -44.1% ), highlighting profit volatility. Over the last four quarters, margins were uneven: net margin moved from a high in 2024-12-31 (≈15.1%) down to low points in 2025-03-31 (≈1.4%) and 2025-09-30 (≈1.9%), before rebounding in 2025-06-30 (≈8.0%) and 2025-12-31 (≈8.1%). Share count decreased from 102.78M (2024-12-31) to 97.30M (2025-12-31), suggesting shareholder return support via buybacks. Balance sheet resilience appears stable-to-improving: total assets rose to $38.97B and equity increased to $2.64B, though net debt also increased modestly to $3.10B. For shareholder returns, the stock is up 14.6% over 1Y and offers a low dividend yield (~0.39%); total shareholder return is therefore primarily driven by price appreciation. Analyst targets ($46–$47) imply moderate upside versus the current price (~$43.63)."

Revenue Growth

Positive

Revenue was down QoQ (-3.8%: $1.1887B to $1.1431B) but up YoY (+4.2%: $1.0972B to $1.1431B). Over the 4-quarter span, revenue fluctuated around the ~$1.0B–$1.19B range, indicating modest underlying growth with timing/volume volatility.

Profitability

Fair

Net Income was up sharply QoQ (+302%: $23.1M to $92.9M) but down YoY (-44.1%: $166.1M to $92.9M). Net margin is volatile: ~15.1% (2024-12-31) fell to ~1.4%–1.9% (2025-03-31/2025-09-30) and rebounded to ~8.0%–8.1% in 2025-06-30 and 2025-12-31, suggesting improvement off the lows but not full recovery.

Cash Flow Quality

Neutral

Cash flow data was not provided, so cash generation quality cannot be directly validated. Still, earnings improved QoQ and EPS rose to $0.98, while dividends are small with a payout ratio of ~17% in the latest quarter—generally supportive of sustainability. Buybacks are suggested by share count reduction.

Leverage & Balance Sheet

Neutral

Total assets increased to $38.97B (+3% QoQ from $38.30B), and equity rose to $2.64B (from $2.61B QoQ). Net debt also increased to $3.10B (from $2.83B QoQ), implying slightly higher leverage pressure, but the balance sheet trend is broadly stable.

Shareholder Returns

Positive

1Y price appreciation is +14.57% (below the >20% momentum threshold), and the dividend yield is ~0.39%. Share count declined from 102.78M (2024-12-31) to 97.30M (2025-12-31), supporting total return via buybacks, but dividend/interest contribution remains modest.

Analyst Sentiment & Valuation

Positive

Latest P/E is ~11.1x, and consensus price targets ($46.67; median $47) are modestly above the current price ($43.63), implying reasonable valuation with some upside. Prior-quarter P/E spikes (e.g., 42x/76x) reflect earnings volatility.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is confident and upbeat (record production, 11.4% ex-significant items ROE, exceeded guidance), but the Q&A reveals a less comfortable operating backdrop. The clearest pressure point is Medicare: management expects Medicare Advantage volume to decline and called the headwinds “very significant,” while leaning on Medicare Supplement as a more resilient, controllable franchise (manufacture + distribution). At the same time, macro risk is explicitly acknowledged—layoffs may help recruiting but increase consumer fear, which management says could weigh on discretionary annuities, life, and long-term care. On capital markets and portfolio risk, they are cautious rather than aggressive: they plan no change in risk parameters and are not seeing valuations/spreads that justify a move to higher-yielding assets. Analyst questions focused on earnings emergence lag, capital deployment timing, and investment allocation risk; management provided guardrails but did not offer upside narratives to offset the Medicare and macro headwinds.

AI IconGrowth Catalysts

  • Total NAP up 15% for full-year 2025 (Consumer and Worksite both record production)
  • Life NAP up 10% full-year; direct-to-consumer life sales up 20% (non-television leads >70% of D2C life sales)
  • Total Health NAP up 22% full-year (Supplemental health +15%, Long-term care +4%; 14 consecutive quarters of growth)
  • Medicare Supplement NAP up 49% full-year and up 92% in Q4 (best Med Supp quarter in 15 years)
  • Annuity collected premiums +9% full-year; +3% in Q4; in-force account values +7% to exceed $13B
  • Brokerage/advisory client assets +24% YoY to >$5B; total accounts +12% full-year

Business Development

  • Completed second Bermuda reinsurance treaty in Q4 2025; management indicated cadence suggests future deals but guidance assumes no additional treaties beyond the two already in place for 2026

AI IconFinancial Highlights

  • Operating EPS (diluted) was $4.40 for the quarter/year period cited; +11% (management also notes full-year operating EPS was $4.02 excluding significant items)
  • Operating EPS ex significant items: +10% in the quarter and +6% for the year; full-year exceeded high end of original guidance
  • Operating ROE (ex significant items) 11.4%; improved from 10% run-rate in 2024; progress toward 12% target ROE in 2027
  • Expense ratio (ex significant items) 18.9% for the full year; better than low end of original guidance
  • Effective tax rate on operating income 20.6% for the year vs 22%–22.5% guidance (reasons: tax credits in Q4, reduced state tax impact, higher tax-exempt interest)
  • Tax/portfolio investment impact: NII allocated to products +6% for the year; new money rate 6.11% (12th consecutive quarter above 6%)
  • Capital return: $386M returned to shareholders in 2025 (+11% vs 2024) with $320M deployed on share repurchases in the year (including $60M in Q4)
  • RBC/capital: consolidated risk-based capital ratio 380%; target RBC range 360%–390% (midpoint consistent with 375% previously stated)
  • Holdco liquidity: $351M end of year vs minimum threshold $150M

AI IconCapital Funding

  • Share repurchases: $320M in 2025 (+14%); $60M in Q4
  • Debt to total capital within target range 25%–28%
  • FABN issued: $400M in the quarter and $750M for the full year
  • Holdco liquidity $351M; minimum holdco liquidity guidance $150M

AI IconStrategy & Ops

  • Tech modernization: 3-year initiative (~$170M total) on track; deployed ~$20M in 2025; expects ~$75M additional deployment in 2026 (free cash flow guidance net of this investment)
  • Worksite fee services exit progressing on schedule; should be largely complete in first half of 2026 (already seeing streamlining benefits)
  • Medicare lead gen diversification: shifting D2C life marketing from TV to web/digital/third-party channels

AI IconMarket Outlook

  • 2026 operating EPS guidance: $4.25–$4.45 (8% increase at midpoint from 2025)
  • 2026 expense ratio guidance: 18.8%–19.2% (expense ratio seasonality: higher in Q1, trending lower through year)
  • 2026 effective tax rate guidance: ~22.5%
  • 2026 fee income: ~$30M (roughly 1/3 in Q1; minimal in Q2/Q3; balance in Q4)
  • 2026 free cash flow: $200M–$250M
  • 2026 ROE trajectory: improvement in run-rate operating ROE by +200 bps through 2027 off ~10% 2024 run-rate
  • 2026 risk-based capital: 360%–390%; minimum holdco liquidity $150M; debt to total capital 25%–28%

AI IconRisks & Headwinds

  • Macro visibility deterioration: management cited 'some of the most lack of visibility I've had' (interest rates/geopolitics variables)
  • Job/layoff environment: could aid recruiting but increases consumer reticence for discretionary products; risk that annuities/life/LTC are more sensitive than Medicare Supplement
  • Medicare Advantage headwinds: management expects MA sales to go down due to marketplace dynamics; carriers paring back plans/benefits; described as 'very significant' headwinds
  • Medicare Advantage distribution fees: management reflected expectations for MA volume pressure in projections, but could not quantify churn/fee impacts precisely; reiterated pressure likelihood
  • Investment universe spread environment: no planned shift to higher-yielding assets because spreads 'not very tight' and valuations 'not cheapened enough'; monitoring software/BDCs but not changing risk parameters

Sentiment: MIXED

Note: This summary was synthesized by AI from the CNO Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (CNO)

© 2026 Stock Market Info — CNO Financial Group, Inc. (CNO) Financial Profile